FDA proposes stripping gender references from regulations, prompting research concerns

The U.S. Food and Drug Administration has issued a proposal to eliminate references to gender in its regulatory language. The change is intended to modernize the rules but has drawn attention from the research community.

Critics warn that removing gender identifiers could create unintended consequences for studies that rely on sex-based data. They argue that clear definitions are essential for designing and interpreting clinical trials.

In a separate development, Louisiana asked the Supreme Court to uphold a decision that blocks access to mailed abortion pills. The request highlights ongoing legal battles over reproductive health policy.

The FDA’s proposal and the legal challenge in Louisiana illustrate the broader regulatory and policy environment that pharmaceutical companies must navigate.